Indian Generics Also Suffer Slowdown In U.S. Economy
This article was originally published in PharmAsia News
Executive Summary
New data suggests Indian generics makers suffered to a large extent in the downturn in the U.S. economy in 2008. According to IMS Health Retail Drug Monitor, drugstore sales in the United States grew by only one percent last year, an important figure since the country accounts for half of the global pharmaceutical market. But generics makers are expected to profit in general because a weaker economy leads to greater emphasis on generics over branded drugs. The large European market rose by two percent during the period ending in October of last year and emerging markets demonstrated a better growth in sales. (Click here for more
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.